TRANSGENRX INC has a total of 15 patent applications. Its first patent ever was published in 2003. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Australia. Its main competitors in its focus markets biotechnology, foods and drinks and pharmaceuticals are MONTREAL INST RECH CLINIQUES, THEREXSYS LTD and MAT MALTA ADVANCED TECHNOLOGIES LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Australia | 2 | |
#4 | United States | 2 | |
#5 | Brazil | 1 | |
#6 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Foods and drinks | |
#3 | Pharmaceuticals | |
#4 | Agriculture | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Animal care | |
#5 | Special foods | |
#6 | Climate change adaptation technologies | |
#7 | Foods | |
#8 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Cooper Richard K | 15 |
#2 | Fioretti William C | 15 |
#3 | Cadd Gary G | 12 |
#4 | Deboer Kenneth F | 4 |
#5 | De Boer Kenneth F | 2 |
#6 | Enright Frederick M | 1 |
Publication | Filing date | Title |
---|---|---|
WO2012051615A1 | Novel vectors for production of glycosylated interferon | |
EP2342224A2 | Novel vectors for production of interferon | |
WO2005062881A2 | Gene therapy using transposon-based vectors | |
BR0305217A | Gene regulation in transgenic animals using a transposon-based vector | |
US7527966B2 | Gene regulation in transgenic animals using a transposon-based vector |